The formation of the granuloma in tuberculosis infection

Seminars in Immunology

Volumn 26, Issue 6, 2014, Pages 601-609

  Orme, Ian M ^a   Basaraba, Randall J ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

Author keywords

Animal models; Granuloma; Immunopathology; Latency versus persistence; Necrosis; Tuberculosis

Indexed keywords

BACTERIAL SURVIVAL; GRANULOMA; GUINEA PIG MODEL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MOUSE MODEL; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; NONHUMAN; REVIEW; TUBERCULOSIS; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GUINEA PIG; IMMUNE EVASION; IMMUNOLOGY; INNATE IMMUNITY; LUNG; LUNG TUBERCULOSIS; MICROBIOLOGY; MOUSE; PATHOLOGY;

CYTOKINE;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GRANULOMA; GUINEA PIGS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; LUNG; MICE; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; TUBERCULOSIS, PULMONARY;

EID: 84920117183     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.09.009     Document Type: Review

References (65)

1. Basaraba R.J. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis 2008, 88(Suppl. 1):S35-S47.
2. Rhoades E.R., Frank A.A., Orme I.M. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis 1997, 78:57-66.
3. Guirado E., Schlesinger L.S. Modeling the Mycobacterium tuberculosis granuloma - the critical battlefield in host immunity and disease. Front Immunol 2013, 4:98.
4. Russell D.G., Cardona P.J., Kim M.J., Allain S., Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009, 10:943-948.
5. Reece S.T., Kaufmann S.H. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis. Curr Opin Microbiol 2012, 15:63-70.
6. Ehlers S., Schaible U.E. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol 2012, 3:411.
7. Orme I.M. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol 2011, 6:161-177.
8. Orme I.M. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis 2014, 94:8-14.
9. Turner O.C., Basaraba R.J., Frank A.A., Orme I.M. Granuloma formation in mouse and guinea pig models of experimental tuberculosis. Granulomatous infections and inflammation: cellular and molecular mechanisms 2003, 65-84. ASM Press, Washington, DC. D.L. Boros (Ed.).
10. Turner O.C., Basaraba R.J., Orme I.M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 2003, 71:864-871.
11. Hunter R.L. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis 2011, 91:497-509.
12. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
13. McShane H., Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis 2014, 94:105-110.
14. Williams A., Hall Y., Orme I.M. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis 2009, 89:389-397.
15. McMurray D.N., Collins F.M., Dannenberg A.M., Smith D.W. Pathogenesis of experimental tuberculosis in animal models. Curr Top Microbiol Immunol 1996, 215:157-179.
16. Wolf A.J., Linas B., Trevejo-Nunez G.J., Kincaid E., Tamura T., Takatsu K., et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007, 179:2509-2519.
17. Davis J.M., Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009, 136:37-49.
18. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
19. Russell D.G., Barry C.E., Flynn J.L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328:852-856.
20. Cardona P.J. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 2009, 37:80-86.
21. Orme I.M. Vaccine development for tuberculosis: current progress. Drugs 2013, 73:1015-1024.
22. Lenaerts A.J., Hoff D., Aly S., Ehlers S., Andries K., Cantarero L., et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007, 51:3338-3345.
23. Ryan G.J., Hoff D.R., Driver E.R., Voskuil M.I., Gonzalez-Juarrero M., Basaraba R.J., et al. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS ONE 2010, 5:e11108.
24. Salgame P. MMPs in tuberculosis: granuloma creators and tissue destroyers. J Clin Invest 2011, 121:1686-1688.
25. Taylor J.L., Hattle J.M., Dreitz S.A., Troudt J.M., Izzo L.S., Basaraba R.J., et al. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 2006, 74:6135-6144.
26. Torabi-Parizi P., Vrisekoop N., Kastenmuller W., Gerner M.Y., Egen J.G., Germain R.N. Pathogen-related differences in the abundance of presented antigen are reflected in CD4+ T cell dynamic behavior and effector function in the lung. J Immunol 2014, 192:1651-1660.
27. Dannenberg A.M., Collins F.M. Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products. Tuberculosis 2001, 81:229-242.
28. Leong F.J., Dartois V., Dick T. A color atlas of comparative pathology of pulmonary tuberculosis 2011, CRC Press, New York.
29. Gonzalez-Juarrero M., Turner O.C., Turner J., Marietta P., Brooks J.V., Orme I.M. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001, 69:1722-1728.
30. Achkar J.M., Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013, 13:250-262.
31. Johnson C.M., Cooper A.M., Frank A.A., Bonorino C.B., Wysoki L.J., Orme I.M. Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Tuber Lung Dis 1997, 78:257-261.
32. Turner J., Frank A.A., Brooks J.V., Gonzalez-Juarrero M., Orme I.M. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp Gerontol 2001, 36:537-545.
33. Brighenti S., Andersson J. Local immune responses in human tuberculosis: learning from the site of infection. J Infect Dis 2012, 205(Suppl. 2):S316-S324.
34. Ordway D., Henao-Tamayo M., Harton M., Palanisamy G., Troudt J., Shanley C., et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 2007, 179:522-531.
35. Shang S., Harton M., Tamayo M.H., Shanley C., Palanisamy G.S., Caraway M., et al. Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis 2011, 91:378-385.
36. Ordway D.J., Shang S., Henao-Tamayo M., Obregon-Henao A., Nold L., Caraway M., et al. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol 2011, 18:1527-1535.
37. Ordway D., Henao-Tamayo M., Orme I.M., Gonzalez-Juarrero M. Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J Immunol 2005, 175:3873-3881.
38. Basaraba R.J., Dailey D.D., McFarland C.T., Shanley C.A., Smith E.E., McMurray D.N., et al. Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis. Tuberculosis 2006, 86:386-394.
39. Basaraba R.J., Smith E.E., Shanley C.A., Orme I.M. Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol. Infect Immun 2006, 74:5397-5401.
40. Via L.E., Lin P.L., Ray S.M., Carrillo J., Allen S.S., Eum S.Y., et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008, 76:2333-2340.
41. Shanley C.A., Ireton G.C., Baldwin S.L., Coler R.N., Reed S.G., Basaraba R.J., et al. Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis. Tuberculosis 2014, 94:140-147.
42. Palanisamy G.S., DuTeau N., Eisenach K.D., Cave D.M., Theus S.A., Kreiswirth B.N., et al. Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis 2009, 89:203-209.
43. Palanisamy G.S., Smith E.E., Shanley C.A., Ordway D.J., Orme I.M., Basaraba R.J. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis 2008, 88:295-306.
44. Sharpe S.A., Eschelbach E., Basaraba R.J., Gleeson F., Hall G.A., McIntyre A., et al. Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis. Tuberculosis 2009, 89:405-416.
45. Rayner E.L., Pearson G.R., Hall G.A., Basaraba R.J., Gleeson F., McIntyre A., et al. Early lesions following aerosol infection of rhesus macaques (Macaca mulatta) with Mycobacterium tuberculosis strain H37RV. J Comp Pathol 2013, 149:475-485.
46. Behr M.A., Waters W.R. Is tuberculosis a lymphatic disease with a pulmonary portal. Lancet Infect Dis 2014, 14:250-255.
47. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69:1847-1855.
48. Ferrara G., Murray M., Winthrop K., Centis R., Sotgiu G., Migliori G.B., et al. Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFalpha drugs. Curr Opin Pulm Med 2012, 18:233-240.
49. Algood H.M., Lin P.L., Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005, 41(Suppl. 3):S189-S193.
50. Kapoor N., Pawar S., Sirakova T.D., Deb C., Warren W.L., Kolattukudy P.E. Human granuloma in vitro model, for TB dormancy and resuscitation. PLOS ONE 2013, 8:e53657.
51. Ordway D., Henao-Tamayo M., Shanley C., Smith E.E., Palanisamy G., Wang B., et al. Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin Vaccine Immunol 2008, 15:1248-1258.
52. Ordway D., Palanisamy G., Henao-Tamayo M., Smith E.E., Shanley C., Orme I.M., et al. The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J Immunol 2007, 179:2532-2541.
53. Shang S., Shanley C.A., Caraway M.L., Orme E.A., Henao-Tamayo M., Hascall-Dove L., et al. Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis. Vaccine 2012, 30:1572-1582.
54. Dharmadhikari A.S., Basaraba R.J., Van Der Walt M.L., Weyer K., Mphahlele M., Venter K., et al. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis 2011, 91:329-338.
55. Helke K.L., Mankowski J.L., Manabe Y.C. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis 2006, 86:337-348.
56. Chiang C.Y., Riley L.W. Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005, 5:629-636.
57. Verver S., Warren R.M., Beyers N., Richardson M., van der Spuy G.D., Borgdorff M.W., et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005, 171:1430-1435.
58. Henao-Tamayo M., Obregon-Henao A., Ordway D.J., Shang S., Duncan C.G., Orme I.M. A mouse model of tuberculosis reinfection. Tuberculosis 2012, 92:211-217.
59. Nardell E., McInnis B., Thomas B., Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986, 315:1570-1575.
60. Ojha A.K., Baughn A.D., Sambandan D., Hsu T., Trivelli X., Guerardel Y., et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol 2008, 69:164-174.
61. Ordway D.J., Shanley C.A., Caraway M.L., Orme E.A., Bucy D.S., Hascall-Dove L., et al. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother 2010, 54:1820-1833.
62. Ackart D.F., Hascall-Dove L., Caceres S.M., Kirk N.M., Podell B.K., Melander C., et al. Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis. Pathog Dis 2014, 70:359-369.
63. Ackart D.F., Lindsey E.A., Podell B.K., Melander R.J., Basaraba R.J., Melander C. Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules. Pathog Dis 2014, 70:370-378.
64. Stead W.W. Pathogenesis of tuberculosis: clinical and epidemiologic perspective. Rev Infect Dis 1989, 11(Suppl. 2):S366-S368.
65. Stead W.W., Bates J.H. Recurrent tuberculosis due to exogenous reinfection. N Engl J Med 2000, 342:1050.